

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

р́І. No. : 10/658,112

Confirmation No.: 3155

Applicant : Filed :

Lewis H. Lambert, Jr. September 8, 2003

TC/A.U.: 1746 Examiner: NA

Title

Treatment of Mycobacterial Disease by Administration of

Bacterial/Permeability-Increasing Protein Products

Docket No.

11699.105017 (ZPR 1007 US)

Customer No.:

20786

Mail Stop Missing Parts Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

REQUEST TO CORRECT FILING RECEIPT UNDER 37 CFR §

Sir:

Please correct the priority application serial number on the filing receipt to correct an inadvertent typographical error. As such, the Domestic Priority data should read:

This application is a CON of 09/782,642 02/13/2001 PAT 6,620,785 which is a CON of 08/626,646 04/01/1996 PAT 6,214,789 which is a CON of 08/285,803 08/04/1994 ABN which is a CIP of 08/031,145 03/12/1993 ABN

A copy of the Official Filing Receipt with the changes noted thereon is enclosed.

We do not believe that any payment is due in relation to this amendment, we hereby authorize the Commissioner to charge any additional fees, or credit any overpayment, to Deposit Account 11-0980.

Respectfully submitted,

Madeline I Johnston, Esq.

Reg. No. 36,174

February 10 2005

King & Spalding, LLP 45th Floor 191 Peachtree Street, N.E. Atlanta, Georgia 30303 404.572.4720





UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEFARING OF COMMI United States Patent and Trademark Offices Address: COMMISSIONER FOR PATENTS PO. Dox 1450 Alexandria, Viginia 22313-1450 www.unpto.gov

FILING OR 371 APPL NO. (c) DATE

ART UNIT FIL FEE REC'D 1746

ATTY.DOCKET NO

DRAWINGS TOT CLMS

IND CLMS

10/658,112

09/08/2003

0.00

29715/33202A

2

23 5

CONFIRMATION NO. 3155

FILING RECEIPT

OC000000013467034°

04743 MARSHALL, GERSTEIN & BORUN LLP 6300 SEARS TOWER 233 S. WACKER DRIVE CHICAGO, IL 60606

RECEIVED

AUG 1 6 2004

MARSHALL GERSTEIN

Date Mailed: 08/10/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Lewis H. Lambert JR., Fremont, CA:

Assignment For Published Patent Application

XOMA CORPORATION, Berkeley, CA;

Domestic Priority data as claimed by applicant

--09/782,642--

This application is a CON of 49/782,682/02/13/2001 PAT 6.551,498 -- 6,620,785 -which is a CON of 08/626,646 04/01/1996 PAT 6,214,789 which is a CON of 08/285,803 08/04/1994 ABN which is a CIP of 08/031,145 03/12/1993 ABN

Foreign Applications

If Required, Foreign Filing License Granted: 08/06/2004

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

'Title

Treatment of Mycobacterial diseases by administration of bacterial/permeability-increasing protein products

Preliminary Class

205

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).